drugset
drugset / Trial / NCT01298765

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

NCT01298765 ↗

Phase 3 Completed 302 enrolled BioDelivery Sciences International
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.

Timeline

Start
2011-03
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified — Other

Indications

neuropathy, painful osteoarthritis